Braden Michael Leonard Acquires 17,716 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) major shareholder Braden Michael Leonard acquired 17,716 shares of the stock in a transaction dated Monday, July 22nd. The shares were bought at an average price of $1.33 per share, for a total transaction of $23,562.28. Following the transaction, the insider now owns 13,602,691 shares in the company, valued at approximately $18,091,579.03. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Braden Michael Leonard also recently made the following trade(s):

• On Thursday, July 18th, Braden Michael Leonard purchased 130,317 shares of Aclaris Therapeutics stock. The shares were purchased at an average price of $1.30 per share, for a total transaction of $169,412.10.
• On Friday, July 5th, Braden Michael Leonard acquired 123,017 shares of Aclaris Therapeutics stock. The shares were purchased at an average price of $1.15 per share, for a total transaction of $141,469.55.
• On Wednesday, July 3rd, Braden Michael Leonard purchased 143,288 shares of Aclaris Therapeutics stock. The shares were acquired at an average price of $1.16 per share, for a total transaction of $166,214.08.
• On Monday, July 1st, Braden Michael Leonard acquired 107,434 shares of Aclaris Therapeutics stock. The stock was acquired at an average price of $1.14 per share, for a total transaction of $122,474.76.
• On Thursday, June 27th, Braden Michael Leonard bought 235,000 shares of Aclaris Therapeutics stock. The shares were acquired at an average price of $1.15 per share, with a total value of $270,250.00.
• On Monday, June 17th, Braden Michael Leonard purchased 150,000 shares of Aclaris Therapeutics stock. The stock was bought at an average price of $1.13 per share, for a total transaction of $169,500.00.
• On Thursday, June 13th, Braden Michael Leonard acquired 528,621 shares of Aclaris Therapeutics stock. The stock was bought at an average price of $1.15 per share, with a total value of $607,914.15.
• On Tuesday, June 11th, Braden Michael Leonard purchased 1,000,000 shares of Aclaris Therapeutics stock. The shares were bought at an average price of $1.08 per share, for a total transaction of $1,080,000.00.

Aclaris Therapeutics Stock Up 0.8 %

Shares of ACRS stock traded up $0.01 during trading hours on Monday, hitting $1.33. 521,498 shares of the company’s stock traded hands, compared to its average volume of 1,258,327. The stock’s fifty day simple moving average is $1.16 and its two-hundred day simple moving average is $1.19. Aclaris Therapeutics, Inc. has a 12-month low of $0.59 and a 12-month high of $10.72. The stock has a market cap of $94.78 million, a price-to-earnings ratio of -1.23 and a beta of 0.27.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. Aclaris Therapeutics had a negative return on equity of 61.03% and a negative net margin of 248.28%. The business had revenue of $2.40 million during the quarter, compared to analysts’ expectations of $1.99 million. On average, equities analysts forecast that Aclaris Therapeutics, Inc. will post -0.78 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ACRS. BML Capital Management LLC increased its position in shares of Aclaris Therapeutics by 1,338.7% during the first quarter. BML Capital Management LLC now owns 9,395,934 shares of the biotechnology company’s stock valued at $11,651,000 after acquiring an additional 8,742,827 shares in the last quarter. Monaco Asset Management SAM bought a new stake in shares of Aclaris Therapeutics in the 4th quarter worth $1,028,000. Vanguard Group Inc. boosted its holdings in shares of Aclaris Therapeutics by 4.4% during the 1st quarter. Vanguard Group Inc. now owns 4,929,775 shares of the biotechnology company’s stock valued at $6,113,000 after acquiring an additional 207,418 shares during the last quarter. Strs Ohio raised its holdings in shares of Aclaris Therapeutics by 256.7% during the fourth quarter. Strs Ohio now owns 193,000 shares of the biotechnology company’s stock valued at $202,000 after purchasing an additional 138,900 shares during the last quarter. Finally, Octagon Capital Advisors LP purchased a new stake in Aclaris Therapeutics in the fourth quarter worth approximately $105,000. 98.34% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. HC Wainwright reaffirmed a “neutral” rating on shares of Aclaris Therapeutics in a research report on Monday. StockNews.com lowered Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, April 2nd. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, Aclaris Therapeutics presently has an average rating of “Hold” and a consensus price target of $22.25.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.